Use of anti-secretory medication: A population-based cohort study

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 5, 2004, Pages 577-583

  Lassen, A ^a   Hallas, J ^a   Schaffalitzky De Muckadell, O B ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DENMARK; DRUG USE; ESOPHAGITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGED; ANTACIDS; COHORT STUDIES; DENMARK; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; LONG-TERM CARE; MALE; MIDDLE AGED; ODDS RATIO; PEPTIC ULCER; PROTON PUMPS;

EID: 4544327828     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02120.x     Document Type: Article

References (28)

1. Lægemiddelstyrelsen. Lægemiddelstatistik 1998-2002 Danmark. København: Lægemiddelstyrelsen, 2003.
2. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317: 452-6.
3. Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12: 797-805.
4. McManus P, Marley J, Birkett DJ, et al. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. Br J Clin Pharmacol 1998; 46: 409-11.
5. Marshall JK, Grootendorst PV, O'Brien BJ, et al. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 2002; 166: 1655-62.
6. Westbrook JI, Duggan AE, McIntosh JH. Prescriptions for antiulcer drugs in Australia: volume, trends, and costs. BMJ 2001; 323: 1338-9.
7. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001; 23: 116-7.
8. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25: 333-40.
9. Malfertheiner P, Megraud F, O'morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
10. Delaney BC, Wilson S, Roalfe A, et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet 2000; 356: 1965-9.
11. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445-8.
12. Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287: 2398-9.
13. WHO Collaborating Center for Drug Statistical Methodology. Classification Index Including Defined Daily Doses (DDD) for Plain Substances. Oslo, Norway: WHO Collaborating Center for Drug Statistical Methodology. 1995.
14. Altman D. Practical Statistics for Medical Research. London, UK: Chapman & Hall, 1991.
15. Lassen A, Hallas J, de Muckadell OB. Eradication of Helicobacter pylori and use of anti-secretory drugs: population-based cohort study. BMJ 2003; 327: 603.
16. Juul KV, Thomsen OO, Nissen A, et al. National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34.582 prescriptions. Scand J Gastroenterol 1998; 33: 928-32.
17. el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-33.
18. Loffeld RJ, van der Putten AB. Rising incidence of reflux oesophagitis in patients undergoing upper gastrointestinal endoscopy. Digestion 2003; 68: 141-4.
19. Roberts SJ, Bateman DN. Prescribing of antacids and ulcerhealing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995; 9: 137-43.
20. Thors H, Sigurdsson H, Oddsson E, et al. Survey of prescriptions for peptic ulcer drugs (ACT class AOB2) in Iceland. Scand J Gastroenterol 1994; 29: 988-94.
21. Cooper AL, Langworthy H, Porter S. Cost-effective prescribing of proton pump inhibitor therapy: an audit in general practice. Int J Clin Pract 2000; 54: 287-92.
22. McBride JE, Pater JL, Dorland JL, et al. Extent and variation of omeprazole prescribing in an elderly population of Ontario. Ann Pharmacother 1997; 31: 411-6.
23. Goudie BM, McKenzie PE, Cipriano J, et al. Repeat prescribing of ulcer healing drugs in general practice - prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996; 10: 147-50.
24. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49: 451-3.
25. Ryder SD, O'Reilly S, Miller RJ, et al. Long term acid suppressing treatment in general practice [see comments]. BMJ 1994; 308: 827-30.
26. Boutet R, Wilcock M, MacKenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 1999; 13: 813-7.
27. Rubin GP, Contractor B, Bramble MG. The use of long-term acid-suppression therapy. Br J Clin Pract 1995; 49: 119-20.
28. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.